In this post, I have attempted to create a one-stop reference point for supply of COVID vaccines to various countries by Serum Institute and Bharat Biotech. This post will be periodically updated.
Indian companies are the major suppliers of vaccines globally due to availability of high quality manufacturers at low prices. Over the next few months, Serum Institute of India and Bharat Biotech are all set to supply billions of doses of the COVID vaccine to the rest of the world. A total of 95 countries have sent requests to India for vaccines.
Apart from COVISHIELD which is in collaboration with AstraZeneca, Serum Institute has also tied up with Novavax for manufacture of over a billion doses of its COVID vaccine, which is still in trials. Four more vaccines of Serum Institute and two of Bharat Biotech are under trials. Serum Institute is by far the larger of the two companies, and this reflects in the total volume of doses being supplied by each.
Serum Institute of India will be supplying upto a billion doses of the vaccine to the following agencies / countries:
India has already placed orders for 11 million doses and is expected to purchase upto 300 million doses of vaccines in total. Out of the purchased quantity, Serum Institute has committed to providing 10 million doses free of cost to India.
GAVI (The Vaccine Alliance) has committed to purchase 200 million doses of COVISHIELD with options to purchase an additional 900 million doses.
UK has already purchased millions of doses of the vaccine for use via their NHS.
Morocco has entered into agreement with China’s Sinopharm and AstraZeneca to supply over 60 million doses of vaccines.
Saudi Arabia also approved the AstraZeneca vaccine for use.
Bangladesh and South Africa have also entered into agreements with Serum Institute for supply of 30 million and 1.5 million doses of COVISHIELD respectively.
Bolivia has entered into agreement with Serum Institute for 5 million doses of COVISHIELD.
Additionally, the Indian government has already committed to supplying millions of doses of COVISHIELD to Bhutan, Nepal, Bangladesh, Maldives, Myanmar and Seychelles free of cost.
Brazil’s government flew in a special aircraft to India for securing two million doses of COVISHIELD.
Ukraine is in talks for purchase of an unspecified number of doses of COVISHIELD.
Bharat Biotech has struck the following deals so far:
India has placed an order of 55 lakh doses of COVAXIN from Bharat Biotech out of which 16.5 lakh would be given free of cost.
Brazil’s private clinics have entered into agreement with Bharat Biotech to purchase 12 million doses of COVAXIN.
Ecuador’s Ambassador to India Hector Cueva Jacome lined up to register for the COVAXIN trial and also publicly lauded India’s vaccine companies, indicating the possibility of purchase agreements with Bharat Biotech.
Indian government will also supply 8 lakh doses of COVAXIN to Mauritius, Phillipines and Myanmar.
Bharat Biotech has tied up with Ocugen to enter the US market with COVAXIN.
Bharat Biotech also entered into a licensing agreement with Washington University School of Medicine in St Louis to manufacture and distribute upto a billion doses of a novel single-dose intranasal vaccine for COVID-19 in all markets except the USA, Japan and Europe. The vaccine is currently in phase 1 trials.